Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

Starting soon · Phase 4

Conditions studied: Septic Shock

In brief

Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.

Key facts

Study ID
NCT06746753
Run by
Wake Forest University Health Sciences
People needed
78
Starts
2026-09-01
Expected to finish
2028-10-07
Last updated by the study team
2026-07-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.